Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Saved in:
| Title: | Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. |
|---|---|
| Authors: | Subbiah, Vivek1,2 (AUTHOR) vsubbiah@mdanderson.org, Dumbrava, Ecaterina Ileana1 (AUTHOR), Jiang, Yunfang1 (AUTHOR), Thein, Kyaw Z.1 (AUTHOR), Naing, Aung1 (AUTHOR), Hong, David S.1 (AUTHOR), Fu, Siqing1 (AUTHOR), Piha-Paul, Sarina A.1 (AUTHOR), Tsimberidou, Apostolia M.1 (AUTHOR), Janku, Filip1 (AUTHOR), Meric-Bernstam, Funda1 (AUTHOR), Kurzrock, Razelle3 (AUTHOR), Falchook, Gerald4 (AUTHOR) |
| Source: | Experimental Hematology & Oncology. 4/20/2020, Vol. 9 Issue 1, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21623619 |
|---|---|
| DOI: | 10.1186/s40164-020-00159-1 |
